1. Lead Researcher: Sergei Grando, M.D., Ph.D., Dr.Sci.

2. Study Title: Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research is to study alternative treatments for the skin disease pemphigus by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to treat autoimmune diseases, inflammatory diseases, and organ transplantation rejection.

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with pemphigus, have active disease, and who are not taking certain prohibited medications

5. Location (if other than UCIMC):
   Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697
   Gottschalk Medical Plaza, University of California, Irvine, One Medical Plaza Drive, Irvine, CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study will extend your normal monthly visits by about 15 minutes, with the exception of the very first visit (30 minutes) and two additional visits (about 30 minutes). Over the next year, this will add approximately 6.5 hours beyond the time commitment for your regular visits. This estimate includes additional travel and wait time for the extra visits outside your normal visits.

7. Anticipated Benefits (if any): You may benefit from participation in this study by decreasing or possibly eliminating your dose of corticosteroids while still controlling your condition.

8. Compensation (if any): none

9. Contact Name, UCI Department, Phone Number and E-mail:
   Patricia Summerville
   UCI Department of Dermatology
   949-824-7103
   psummerv@uci.edu

Signature of Lead Researcher: ____________________________ Date: ___________

IRB Approval Granted on:
Approved by IRB on: 03/04/11   HS# 2010-7844   Void After: 02/24/12

IRB USE ONLY - DO NOT ALTER THIS FOOTER